source
- Intellia identifies HLA allele linked to severe liver enzyme spikes in ATTR gene therapyIn November 2025, a patient died after receiving Intellia Therapeutics' investigational gene silencer for transthyretin amyloidosis, prompting a safety review of the company’s ATTR gene therapy pro…
- BlossomHill and Latigo close IPO week with $496 million raisedBlossomHill Therapeutics, a cancer‑focused biotech, completed its initial public offering this week. Latigo, a company developing non‑opioid pain treatments, also went public at the same time. To…